Overview
Background
Dr Chloe Tyson is a General Practitioner, medical educator, and researcher with expertise in general practice, antidepressant deprescribing, lifestyle medicine, complex and chronic care, and preventive healthcare. She is a Senior Lecturer in the General Practice Clinical Unit at the University of Queensland Medical School, where she works across undergraduate teaching, assessment, and learning-resource development.
Her current research follows the RELEASE antidepressant tapering plans into everyday general practice: how GPs use them, what gets in the way, and what would make deprescribing more workable. That work is supported by an RACGP Academic Post (2025–2026). Clinically, she works with people whose problems do not fit a standard appointment, using a lifestyle-medicine approach to persistent fatigue, gut and hormonal problems, inflammation, and other unresolved chronic presentations.
Her broader interests include:
- General practice and primary care implementation
- Antidepressant deprescribing and withdrawal-informed tapering
- Lifestyle medicine and whole-person care
- Complex and chronic conditions
- Preventive health and health optimisation
- Mental health in primary care
- Medical education, assessment and resource development
Dr Tyson is committed to strengthening general practice as a setting for complex care, deprescribing, and whole-person medicine, and to building that capacity in the next generation of doctors.
Availability
- Dr Chloe Tyson is:
- Available for supervision
Fields of research
Research interests
-
Antidepressant deprescribing in general practice
I study how GPs use structured tapering plans to support patients stopping long-term antidepressants. My current work examines implementation of the RELEASE hyperbolic tapering protocols in Australian general practice, including barriers, enablers, and how plans are adapted in routine care. The aim is safer deprescribing, fewer misidentified withdrawal symptoms, and practical tools GPs will actually use.
-
Hyperbolic tapering and antidepressant withdrawal
I work on slow, dose-sensitive tapering methods designed to reduce antidepressant withdrawal. This includes how hyperbolic tapering plans perform in real GP settings, how patients and clinicians distinguish withdrawal from relapse, and what support is needed at low doses. The focus is translating deprescribing evidence into usable primary-care protocols.
-
Lifestyle medicine in primary care
I am interested in how lifestyle medicine can be applied in general practice for mental health, chronic illness, and prevention. This includes diet, sleep, movement, and other modifiable drivers as part of deprescribing and whole-person care. I also teach and develop resources for medical students in this area.
-
Functional medicine in general practice
I apply a functional medicine approach in primary care to investigate drivers of persistent symptoms, including gut, hormone, nutrient, inflammation, and nervous-system factors. This work sits alongside deprescribing and lifestyle medicine, with a focus on patients whose problems are unexplained or incompletely treated by standard pathways. I am interested in how this model can be used rigorously in Australian general practice.
Research impacts
Dr Chloe Tyson’s research explores how general practice can support people to stop long-term treatment safely, and how lifestyle medicine can be used in complex and chronic care.
Her early publications examined the experience of adults who decided to cease long-term topical steroid use, documenting why they stopped, what withdrawal involved, and how little structured support they were offered (Dermatitis 2021). She has also written on the effect of the COVID-19 pandemic on junior doctors’ training and career progression (Medical Journal of Australia 2021).
Her current work turns that same question to antidepressants. Through an RACGP Academic Post (2025–2026) she is studying how GPs use the RELEASE tapering plans in everyday practice: what helps, what gets in the way, and what would make deprescribing more workable. That study is not yet published. She presented related RELEASE work at AAAPC 2025.
The practical outcomes of this research are already evident in:
- Structured, withdrawal-informed tapering used in clinical care rather than abrupt dose cuts
- Recognition and support for people navigating topical steroid withdrawal
- Lifestyle-medicine approaches to persistent fatigue, gut and hormonal problems, and other unresolved chronic presentations
- Teaching UQ medical students to treat deprescribing and whole-person care as ordinary general practice
Together, these initiatives contribute to a broader shift toward safer deprescribing and person-centred care in Australian primary healthcare.
Works
Funding
Past funding
Supervision
Availability
- Dr Chloe Tyson is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Media
Enquiries
For media enquiries about Dr Chloe Tyson's areas of expertise, story ideas and help finding experts, contact our Media team: